Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856
Autore:
Lester, EP; Petroni, GR; Barcos, M; Johnson, JL; Millard, FE; Cooper, MR; Omura, GA; Frei, E; Peterson, BA;
Indirizzi:
Lakeland Med Ctr, St Joseph, MI USA Lakeland Med Ctr St Joseph MI USALakeland Med Ctr, St Joseph, MI USA CALGB Biostat Ctr, Durham, NC USA CALGB Biostat Ctr Durham NC USACALGB Biostat Ctr, Durham, NC USA Roswell Pk Canc Inst, Buffalo, NY 14263 USA Roswell Pk Canc Inst Buffalo NY USA 14263 anc Inst, Buffalo, NY 14263 USA USN, Med Ctr, San Diego, CA 92152 USA USN San Diego CA USA 92152USN, Med Ctr, San Diego, CA 92152 USA Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem,NC USA Wake Forest Univ Winston Salem NC USA prehens Canc, Winston Salem,NC USA Univ Alabama, Birmingham, AL USA Univ Alabama Birmingham AL USAUniv Alabama, Birmingham, AL USA Dana Farber Canc Inst, Boston, MA 02115 USA Dana Farber Canc Inst Boston MA USA 02115 Canc Inst, Boston, MA 02115 USA Univ Minnesota, Minneapolis, MN USA Univ Minnesota Minneapolis MN USAUniv Minnesota, Minneapolis, MN USA
Titolo Testata:
CANCER INVESTIGATION
fascicolo: 5, volume: 19, anno: 2001,
pagine: 447 - 458
SICI:
0735-7907(2001)19:5<447:CDVPAE>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CLINICAL-TRIALS; HYBRID REGIMEN; DOSE INTENSITY; MOPP; THERAPY; LYMPHOMA; LEUKEMIA; ABVD;
Keywords:
advanced stage; chemotherapy; cyclophosphamide; doxorubicin; etoposide; Hodgkin's disease; prednisone; vincristine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Lester, EP Oncol Care Associates, 820 Lester Ave, St Joseph, MI 49085 USA Oncol Care Associates 820 Lester Ave St Joseph MI USA 49085 USA
Citazione:
E.P. Lester et al., "Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856", CANCER INV, 19(5), 2001, pp. 447-458

Abstract

Successful treatment of advanced-stage Hodgkin's disease (HD) may critically depend on dose intensity. Because mechlorethamine, Oncovin, procarbazine, and prednisone (MOPP), aid Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) are not suitable for major dose escalation, we evaluated the activity and toxicity of combined cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) in advanced HD, here used at conventional dose intensity, as a preparatory study prior to using this regimen at higher dose intensity. Ninety-two patients were treated with CHOPE (cyclophosphamide, 750mg/m(2), day 1; doxrudicin, 50mg/m(2), day 1; vincristine, 1.4mg/m(2), day 1 and 8; prednisone, 100 mg/day, days 1-5; and etoposide, 80 mg/m(2), days 1, 2, and 3) every 21 days. All had advanced HD with no prior chemotherapy with 46% stage IV, 63% with B symptoms, and 57% with bulky disease (>5 cm). Radiation and growth factor support were not permitted. Full-dose vincristine (not capped at maximum 2 mg/dose) was used in the first 33 patients. An initial cohort of 41 patients was treated with four cycles of CHOPE to evaluate safety and efficacy followed by four cycles of ABVD. A second cohort of 51 patients was treated with 6-8 cycles of CHOPE alone. Toxicity was generally acceptable and primarily hematologic, with neutrophils <500 in 63% of cohort I and 90% of cohort II, and platelets < 25,000 in 7% of cohort I and 8% of cohort II. The long-term neurotoxicity of full-dose, high-intensity vincristine was acceptable and largely reversible. In cohortI, 92% of patients achieved a complete response (CR) or partial response (PR) with four cycles of CHOPE and 85% were in CR after four additional cycles of ABVD. In cohort II, 77% achieved a CR with 6-8 cycles of CHOPE alone. FFS was 76% in cohort I and 59% in cohort II, with a median follow-up of 8.2 and 5.7 years, respectively. CHOPE, at conventional close intensity as used here, is an effective first-line regimen for the treatment advanced-stage HD and may warrant evaluation using higher closes of cyclophosphamide and etopaside with granulocyte colony stimulating factor (G-CSF) support.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 22:00:01